Phase 1 N=30 Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
Epilepsy
Primary: Maximum Drug Concentration (Cmax) — 9469; 9867; 15067; 17309 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=12 Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers
Diseases, Metabolic · Insulin Sensitivity
Primary: Flow Mediated Dilation — 10.3; 8.9; 9.2; 9.1 percentage of brachial artery diameter
Phase 1 N=40 An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Epilepsy
Primary: Cmax - Peak Plasma Concentration — 14286.790; 18677.265; 15055.632; 14974.79 ng/mL
Phase 2 N=33 Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Breast Cancer
Primary: Time to Progression — 7.4 months
N/A N=100 Comparison of VF Induction Techniques During Medtronic ICD Implant (VF) (ICD)
Cardiomyopathy
Primary: Sustained Ventricular Fibrillation — 38; 35 participants
N/A N=136 Chiropractic Management of Chronic Lower Back Pain in Older Adults
Chronic Low Back Pain
Primary: Symptoms of Chronic Lower Back Pain as Measured With the Visual Analog Scale (VAS) — 26.32; 20.45 percentage of change from baseline to 5
Phase 1 N=86 A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Allergic Asthma · Atopic Dermatitis · Allergic Rhinitis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 8; 2; 2; 1 participants
N/A N=4,635 Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
Psoriatic Arthritis
Primary: Mean Change From Baseline in Disease Activity Score (DAS)28 — -1.7; -1.9; -1.9; -2.0 score on a scale
Phase 1 N=16 Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
Melanoma
Primary: Determine Dose Limiting Toxicities (DLTs) of VELCADE When Administered in Combination With IFN-α-2b to Patients With Metastatic Malignant Melanoma. — 3; 1 toxicities
N/A N=20 Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time
Post-anesthesia Recovery · Orientation
Primary: Re-orientation Time — 24.5; 19.5 minutes
Phase 3 N=647 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
Chronic Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 94.0; 93.1; 96.3 percentage of participants — p=<0.001
Phase 4 N=32 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Type 2 Diabetes · Hypertension
Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg
N/A N=359 Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma
Chronic Pain
Primary: Numeric Rating Scales of Pain Over Past Week (11 Point Likert Scale) — 4.66; 3.80; 4.92; 3.30 units on a scale
Phase 1 N=18 A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers
Epilepsy
Primary: Number of Adverse Events Reported — 10; 7; 7 Number of adverse events reported
Phase 3 N=330 A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Adverse Events (AE) During the Treatment Phase — 327; 268; 256; 177 participants